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Abstract
Cancer is a disease driven by a combination of inherited risk alleles coupled with the acquisition of somatic mutations,
including amplification and deletion of genomic DNA. Potential relationships between the inherited and somatic aspects of
the disease have only rarely been examined on a genome-wide level. Applying a novel integrative analysis of SNP and copy
number measurements, we queried the tumor and normal-tissue genomes of 178 glioblastoma patients from the Cancer
Genome Atlas project for preferentially amplified alleles, under the hypothesis that oncogenic germline variants will be
selectively amplified in the tumor environment. Selected alleles are revealed by allelic imbalance in amplification across
samples. This general approach is based on genetic principles and provides a method for identifying important tumor-
related alleles. We find that SNP alleles that are most significantly overrepresented in amplicons tend to occur in genes
involved with regulation of kinase and transferase activity, and many of these genes are known contributors to
gliomagenesis. The analysis also implicates variants in synapse genes. By incorporating gene expression data, we
demonstrate synergy between preferential allelic amplification and expression in DOCK4 and EGFR. Our results support the
notion that combining germline and tumor genetic data can identify regions relevant to cancer biology.
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Introduction
Cancer is a disease of two related, but karyotypically distinct
genomes: germline and somatic. Researchers typically focus on
identifying genetic alterations by exclusively studying either the
germline genome or the somatic genome. Germline genetic
variants that play key roles in tumor biology (e.g., risk alleles) have
typically been discovered using linkage and, more recently,
association studies. On the other hand, somatic genetic elements
important for tumor biology, such as amplifications, deletions, and
point mutations, are usually identified by patterns of recurrence
across tumor samples. Given the kinship between these two
genomes, however, studies of cancer biology should be amenable
to population genetic analysis, since the tumor cells can be
considered descendants of a progenitor cell. In the population of
tumor cells, lineages are subject to somatic versions of mutation,
drift and selection [1]. We hypothesize that integrating germline
allelic (i.e., genotypic) information with somatic amplification
events could yield novel insights into the alleles that undergo
selection during tumor evolution.
Associations between cancer risk alleles and somatic patterns are
beginning to appear in the literature with increasing frequency.
Preferential allelic amplification at candidate risk loci has been
convincingly demonstrated in several mouse studies [2,3] as well as
in the analysis of the AURKA oncogene in humans [4,5].
Additionally, a germline risk allele for colorectal cancer was
demonstrated to be preferentially amplified (relative to the wild
type allele) in tumors that were heterozygous for this single
nucleotide polymorphism (SNP) [6]. More recently, a somatically
acquired mutation in JAK2 for myeloproliferative disorders was
shown to arise preferentially on a particular haplotypic back-
ground [7–9]. These targeted studies of specific loci provide
compelling evidence for the relationships between the germline
and somatic genomes. One of the goals of our study is to perform a
genome-wide query for such relationships.
We have developed a battery of statistical methods to query
tumor DNA data for preferential allelic amplification [10]. These
methods are designed to identify alleles that have likely been
positively selected during tumor evolution within areas of copy
number gain (Figure 1; Materials and Methods). One of these
statistical tests, termed the amplification distortion test (ADT), is
closely related to a well-known genetic test of association and
linkage, the transmission disequilibrium test (TDT) [11]. Consider
an example where N =100 tumors harbor an amplification and
are heterozygous at a particular SNP locus (whose alleles are
arbitrarily labeled A and B). Under the null hypothesis, on average
PLoS Genetics | www.plosgenetics.org 1 September 2010 | Volume 6 | Issue 9 | e100108650 tumors will amplify one allele, and the other 50 will amplify the
alternate allele since tumors typically amplify one of the two
parental chromosomes [12]. In this sense, amplification is a
somatic analog of Mendelian 50:50 transmission in germline
genetics. Significant deviations from a 1:1 ratio (Figure 1B) are
inconsistent with this null hypothesis and suggest that the
particular allele – or a variant linked to that allele within the
same amplified region – is advantageous to the tumor when
amplified. Formally, we compare the observed number of
germline heterozygotes amplifying the A allele to the Binomial(N,
p=0.5) distribution to obtain a two-sided P-value (Materials and
Methods and [10]). Similar to the TDT, the ADT is robust to
population stratification because the non-amplified homolog
provides a perfectly matched control.
The recent National Cancer Institute-directed initiative, the
Cancer Genome Atlas (TCGA; [13]), provides an ideal resource to
test our hypothesis, furnishing SNP array data from multiple
platforms across hundreds of glioblastoma multiformae tumors
and matched normal samples. Since SNP arrays contain both the
allelic and amplification information at hundreds of thousands of
loci across the genome, the data are well-suited for our allelic
distortion analysis. For each patient in the study, we made use of
TCGA-generated SNP genotypes in the germline, as well as
amplification status (generated on three separate probe hybrid-
ization-based platforms) and allelic amplification status for
matched tumor DNA.
Results
TCGA recently published (TCGA, 2008) the first report from a
pilot study of over 200 human glioblastoma samples. As part of that
study, the tumor DNA was interrogated at some 1.8 million loci using
the Affymetrix SNP array 6.0, over 236,000 loci using the Agilent
CGH microarray 244A, and at about 550,000 loci using the Illumina
HumanHap550 array. We restricted our analysis to the 178
individuals for whom both germline and tumor array data from the
Illumina platform were available. From these data, we extracted
allelic copy number on a SNP-by-SNP basis; that is, for each
individual, we inferred amplification status at each SNP locus, also
identifying the amplified alleles in amplicon SNPs. As shown in
FigureS1(andobservedintheTCGAmanuscript),commonly(.5%
of samples) amplified loci arerestricted to several discrete – but wide –
genomic regions. Such regions have a median length of 166 kb, and
regions amplified in at least 15% of samples are usually even longer
(median length 382 kb). Such broad regions of recurrent amplifica-
tion can make it difficult to identify the target of these amplifications.
From a statistical standpoint, although we apply our test
statistics across the genome, the ADT is not a genome wide test in
the conventional sense because statistical power is expended only
in a fraction of the genome. In practice, we only test loci with an
amplification frequency sufficiently large to detect allelic selection.
The power to detect selected allelic amplification of a SNP
depends on its amplification frequency as well as its heterozygosity
Figure 1. Biological rationale for selected allelic amplification
in the tumor. (A) The individual inherits an oncogenic variant from the
maternal chromosome M (top). This variant is not directly typed, but is
captured via linkage disequilibrium by surrounding array SNPs (labeled
with nucleotide residue). The paternal chromosome P harbors the wild-
type allele. In the tumor environment (bottom panel), the oncogenic
allele is activated via amplification, which confers a selective growth
advantage to the cell. The amplified haplotype is detected from the SNP
array data, and its preferentially amplified state is revealed through
analysis of data from hundreds of patients. (B) In SNP array data, the
underlying biological phenomenon will manifest itself in an abundance
of amplicons harboring alleles that tag the inherited variant that
provides a selective advantage when amplified. The ADT tests for over-
transmission of a particular allele from heterozygous ‘‘parent’’ cells to
the ‘‘affected’’ (amplified) homolog in the tumor cell and examines
deviations from the null hypothesis of a 1:1 transmission ratio.
doi:10.1371/journal.pgen.1001086.g001
Author Summary
Cancer is a disease of two distinct, but related, genomes:
the inherited genome and the tumor genome. Despite the
fact that the tumor genome arises from the germline, the
genomes are typically studied as separate entities. For
example, germline genetic studies focus on how inherited
variation is related to a particular trait such as disease risk,
whereas tumor genetic studies focus on areas of recurrent
aberrations such as amplifications to identify genes
involved in tumor biology. In this study, we integrated
both germline and tumor genetic information to pinpoint
areas of the human genome that are likely undergoing
selection during the evolution of the tumor. Our results
support the notion that combining germline and tumor
genetic data can identify regions relevant to cancer
biology.
Integrating Germline and Tumor Genomic Data
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with at least nine heterozygote calls in amplified samples have a
chance of achieving a nominal two-tailed P-value ,0.005. By
deciding a priori that P-values above this level will not be
considered significant in downstream analysis, we dramatically
reduced the candidate loci under interrogation (Figure S2),
decreasing the de facto number of SNPs to be tested by 91.9%
from 547,458 to 44,132. This represents a far smaller multiple
testing burden than in germline genome wide association studies
(GWAS). Such reduction in testing burden improves our power to
detect true effects.
Figure 2A presents the amplification distortion signals for SNPs
tested along the genome. The statistical association for all but the
top-scoring SNPs closely follows the distribution expected under
the null hypothesis (Figure 2B), attesting to the validity of the
assumptions. Although no single SNP achieves genome-wide
significance, our results do yield a larger number of SNPs with
lower P-values than would be expected by chance. Specifically,
given the distribution of amplified heterozygotes in our data, we
would expect an average of 114 SNPs to attain a P-value below
0.005 (95% confidence interval 98–132) under the null hypothesis
of no random allelic amplification (Materials and Methods). In the
actual data, 139 SNPs surpass this threshold (Table S1). This
suggests that a subset of the SNPs among these top 139 is likely
subject to selective allelic amplification. We checked the level of
linkage disequilibrium (LD) these SNPs possess in HapMap CEU
data (Table S1); 40 of these 139 SNPs are in strong LD in
HapMap (r
2$0.7) with at least one other SNP within this set of 40
(Table S1, Figures S3, S4, S5). Note that our permutation scheme
preserves LD structure, so that blocks of SNPs in LD can jointly
contribute much of the signal not only in the actual data, but also
during each permutation. Therefore, the 139 SNPs are still indeed
more than expected by chance.
We should point out that one potential artifact arises from the
fact that a germline copy number variant (CNV) gain might
appear to be a somatic amplification when compared with the
signal intensities from pooled normal samples. However, our
methodology guards against this artifact in two ways (Materials
Figure 2. Genome wide ADT analysis of 178 TCGA glioblastoma samples. Manhattan-style plot (A) of amplification distortion P-value (y-axis,
log10 scale) along the genome (x-axis). Save for the strongest hits, the ADT statistic follows the distribution expected under the null hypothesis, as
demonstrated by the quantile-quantile plot (B) of P-values (log10 scale). Only SNPs with nine or more amplified heterozygous samples are presented,
to avoid effects of discrete probabilities in a small sample.
doi:10.1371/journal.pgen.1001086.g002
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intensity is greater than that of all normal samples in the study
(Materials and Methods). Second, we call the amplified allele only
if its allelic intensity is considerably larger in the tumor than in the
matched normal. Finally note that, of our top 139 SNPs, only 23
(16.5%) are harbored in gains reported in the Database of
Genomic Variants (DGV) (http://projects.tcag.ca/variation/),
and of these only 8 are reported in more than three individuals
in the database. Therefore, it is quite unlikely that germline CNVs
significantly contribute to the ADT signal.
To investigate whether certain classes of genes may be driving
our signals, we mapped each of the top 139 SNPs to the nearest
gene (within at most 100 kb), which yielded 73 unique genes
(Table S1). All but 22 of the 139 SNPs fell within 100 kb of a
transcribed region, and 53 of the genes had single SNPs mapping
to them. The largest number of significant SNPs mapping to the
same gene was seven, all lying within the transcribed region of
NSPR1 (see Table S1 for r
2 LD values). We performed a gene
ontology (GO) analysis [14] on the gene set to query for
enrichment in specific annotations (Materials and Methods). The
control set of genes for such analysis deserves special attention in
this study, as gene sets may be over represented among our signals
simply because they are over represented in amplified regions. To
distinguish the signal driven by genes undergoing allelic selection
from that driven by more general (non-allelic) amplification, this
analysis was conducted by comparing our gene set with genes
harboring (or near) SNPs that are recurrently amplified in our
data. Thus, any observed enrichment in GO terms is above and
beyond that which is due solely to general somatic amplification.
This analysis allows us to query for signals from the allele-specific
selection, controlling for those due to somatic amplification alone.
The results are shown in Table 1 and Figure S6.
Among our five significant (FDR q-value ,0.1) GO enrich-
ments is the cellular component term synapse (P=0.0006). Of the
73 genes harboring (or very near) SNPs below the ADT threshold
of P-value,0.005, six (CADPS2, CHRM2, CHRNA4, GRM8,
MAGI2, and SNAP25) possess this annotation. Notably, the
brain-related enrichment is independent of synapse related genes
undergoing amplification in brain tumors, since general amplifi-
cation is controlled for in this analysis. Therefore, the synapse
annotation emerged strictly from the ADT selection signal among
SNPs already in regions amplified in this brain-tissue tumor. This
may be indicative of tumor selection for particular variants in these
specific synapse-annotated genes.
Interestingly, the most significantly enriched GO terms (Table 1)
were positive regulation of kinase activity (P=9.03610
25;
Benjamini-Hochberg corrected q-value 0.0471) and positive
regulation of transferase activity (P=0.000132; Benjamini-Hoch-
berg corrected q-value 0.0471). The six genes in our gene set
associated with these GO terms are AGK, DGKB, EGFR, INSR,
KIT, and RELN. Each of these genes is the closest to a single
significant SNP, with the exceptions of EGFR with two such SNPs,
and RELN with three such SNPs (see Table S1 for r
2 LD values).
Furthermore (Table S1), each harbors one or more of the 139
SNPs within its transcribed region, with the exception of DGKB
whose associated SNP is 66 kb downstream. To investigate the
relative dependencies between the amplifications of these six
genes, we examined the frequencies of their co-amplifications on a
sample-by-sample basis. Of the six, four (AGK, DGKB, EGFR, and
RELN) are located on chromosome 7. As expected, amplifications
of these genes tend to co-occur far more often than would be
expected by random assortment (Fisher’s exact test P ,10
220),
largely due to the fact that amplicons often encompass most or all
genes on the chromosome. The other two genes are located on
chromosomes 4 (KIT) and 19 (INSR). Surprisingly, INSR is co-
amplified with chromosome 7 genes in a statistically significant
manner (Fisher’s exact test P ,10
26 for co-amplification with
EGFR, odds ratio 14.2). On the other hand, KIT amplification is
anti-correlated with that of the genes on chromosome 7 (P=0.05
for anti-correlation with EGFR, odds ratio 0.5). Figure 3 provides
an overview of the amplification association structure among these
Figure 3. Heatmap of correlation, as measured by odds ratio
estimates, between amplification status among six kinase/
transferase activity genes showing signs of somatic allelic
selection. Values above one indicate amplification correlation, below
one anti-correlation. Fisher’s exact P-values are given in each heatmap
pixel.
doi:10.1371/journal.pgen.1001086.g003
Table 1. Gene ontology analysis results.
GO term P-value q-value Population Count Study Count
positive regulation of protein kinase activity 9.03E-05 0.0471 30 6
phosphatase binding 3.20E-04 0.074 6 3
peptidyl-tyrosine phosphorylation 3.46E-04 0.074 14 4
synapse 6.24E-04 0.0851 42 6
positive regulation of catalytic activity 6.37E-04 0.0851 76 8
All terms showing enrichment (q-value ,0.1) among genes identified by ADT analysis, as compared to the reference set of recurrently amplified genes, are shown.
doi:10.1371/journal.pgen.1001086.t001
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and/or alternative pathways that a tumor engages.
Given the preferential allelic amplification observed in some
SNPs, we reasoned that an allele undergoing selection when
amplified in a tumor may have an effect on disease risk as a
germline predisposition variant. This principle has been previously
demonstrated in mice [3] and in humans [6–9]. We therefore
compared our list of the top 139 SNPs from our ADT analysis with
the 406 SNPs reported in a recent GWAS for glioblastoma [15].
The rationale is that the variant that is selectively amplified in
glioblastoma tumors may actually predispose the carrier to the
initiation of the tumor, and thereby occur at a higher frequency in
cases as compared to controls.
A pair of SNPs, rs4367471 and rs4132013 (r
2=0.78 in CEU
HapMap population, Table S1) within a single haplotype block (in
the European populations) in an intron of the LHFPL3 gene,
appears on both lists. Permutation analysis shows that an overlap of
two or more SNPs between lists of these sizes (Materials and
Methods) would be expected by chance only 2.1% of the time
(P=0.021). This is remarkable since the ADT makes use of no
population control genotypes, while the GWAS study does not take
tumor DNA into account. For both SNPs, the minor allele is
overrepresented on amplified chromosomes (in the present study)
and among glioblastoma cases (in the Wrensch et al GWAS).
Among 24 amplified heterozygotes for rs4367471 in our study, 20
amplify the minor allele (P=0.0015), while 27 of 32 amplified
heterozygotes for rs4132013 amplify the minor allele (P=0.00011).
In the GWAS study, the rs4367471 minor allele frequency was 0.28
for glioblastoma cases, as compared to 0.23 for the disease-free
controls (P=0.00022). Similarly, the rs4132013 minor allele
frequency was 0.24 for cases as compared to 0.19 for controls
(P=0.00042). The odds ratios were 1.28 for both SNPs after
adjusting for population structure with the Eigenstrat software [16].
The selective advantage gained by a cell amplifying a specific
allele of a gene may be acting through direct changes in a gene
product (e.g., a missense SNP) or by regulatory changes that
modulate the quantity of gene product. The latter option is a
testable hypothesis – it predicts that the amplification of the
selected-for variant will be associated with elevated transcript
expression levels. To investigate whether any of the detected
signals of selected allele-specific amplification associates with
expression, we integrated the expression data from the tumor
samples with the genotype and amplification status. We considered
Affymetrix U133A expression array data from the 154 individuals
in our sample set for which the data was available from the TCGA
website. Our list of top SNPs includes 65 whose nearest (as
measured by base pair distance to transcribed region) gene is
represented on the expression array. Of the 65 SNPs, only 28 had
at least 5 examples of each SNP allele being amplified among the
154 samples, and were thus available for testing this association.
Topping this list of 28 SNPs were rs6959338 and rs13222385,
intronic variants in DOCK4 (chr 7q31.1) and EGFR (chr 7p11.2),
respectively: rs6959338 shows amplification of the T allele over the
C allele in 33 of 41 amplified heterozygotes (P=1.1610
24);
rs13222385 amplifies the G allele over the A allele in 35 of 45
amplified heterozygotes (P=2.5610
24). Intriguingly, the expres-
sion data shows statistically significantly higher expression in
samples amplifying the selected-for allele than in those amplifying
the other allele (Figure 4) in both DOCK4 (P=0.027) and EGFR
(P=0.015). To pursue this idea further, we tested the expression
levels of the genes immediately flanking EGFR and DOCK4 for
association with amplification of the selected-for alleles. We were
interested to discover that LANCL2, a gene 158 kb downstream
from EGFR, has statistically significantly higher expression in
rs13222385 heterozygotes amplifying the G allele than those
amplifying the A allele (P=0.0371). Taken together with the
SNP’s association with EGFR expression levels, this finding could
point to a regulatory element, such as an enhancer for the allele or
a linked variant.
Discussion
We have presented a novel genome wide approach to identify
genetic variants that are preferentially selected, via amplification,
during tumor evolution. The ADT approach is statistically
rigorous and is robust to the confounding effects of population
stratification. The non-amplified chromosomal homolog provides
the ideal matched control for the amplified homolog, as it comes
from the same individual. Although no single SNP individually
achieves genome-wide significance under the ADT (likely due to a
lack of power owing to limited sample size [10]), our data does
show enrichment in strong ADT signals as compared to chance.
Currently, we are performing similar analyses in areas that have
undergone copy number loss.
Our integrated analysis of genes harboring (or near) SNPs
undergoing apparent allelic selection has revealed intriguing
pathways and annotations. As revealed by the GO analysis, many
of the variants showing ADT signals with P-values ,0.005 are
located within genes related to kinase activity. The fact that both
the EGFR and KIT kinases reach statistical significance is of
particular interest. KIT expression is often observed in gliomas,
and imatinib (which is known to inhibit c-Kit) is currently being
evaluated in clinical trials [17–21]. The correlation/anti-correla-
tion relationships among these implicated genes may highlight
glioblastomas that utilize different pathways and may therefore
represent distinct subtypes of tumors that may be clinically
relevant as has been recently described [22].
We also observed particular instances of the selectively
amplified alleles driving higher expression in DOCK4 and EGFR.
DOCK4 was originally isolated in a screen to identify homozygous
genomic deletions during tumor progression in a mouse model and
is part of a larger family of atypical guanine exchange factor (GEF)
for Rho family GTPases [23]. Rho GTPases are highly conserved
molecular regulators of cytoskeletal dynamics and influence many
cellular processes including cell polarity and migration [24].
Interestingly, it has been previously shown that suppression of
DOCK4 RNA reduces dendritic growth and branching in
hippocampal neurons, while overexpression enhances these
processes [25]. Moreover, increases in Dock180 levels, another
Dock family member, enhanced migratory and invasive capacity
in vitro, while inhibition of expression significantly reduced glioma
cell invasion in vitro [26]. Therefore, we speculate that DOCK4
influences the invasive potential of gliomas and that the DOCK4
alleles may differentially modulate this potential. The role of EGFR
in glioma biology is well established [27] (and references therein).
Somatically acquired mutations of EGFR are commonly (,40%–
50%) observed in gliomas, and the EGFR pathway is commonly
targeted in this disease [13,28–32]. Our results further substantiate
the importance of EGFR and demonstrate that particular alleles
play important roles in determining EGFR expression levels. It will
be of interest to study if expression differences in this gene lead to
amplified or diminished phenotypic consequences. Indeed, a
recent article demonstrates that subtle alterations in expression
levels can lead to dramatic phenotypic consequences [33].
The apparent selection of specific inherited alleles when
amplified is consistent with several biological interpretations.
The data can be considered in the context of Knudson’s two-hit
hypothesis [34] in that the associated SNP alleles are inherited
Integrating Germline and Tumor Genomic Data
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provide a selective advantage when amplified. Indeed, it has been
demonstrated that inherited alleles of a locus (e.g., the Arg72 and
Pro72 variants of TP53) can have differential mechanistic effects
(e.g., apoptotic potential) [35]. Another explanation is that cis-
acting germline determinants influence the acquisition of somatic
mutations, which are subsequently acted on by selection. Elegant
experiments supporting this hypothesis in mice and humans have
recently been published [7–9,36]. Third, one may hypothesize that
a somatic mutation provides a selective advantage only when
amplified on a specific haplotypic background, or is selected
against if the mutation arises on other allelic backgrounds; that is,
only certain alleles will tolerate the somatic mutation.
Since selection implies function, the loci identified in this study
are high-priority candidates for further investigation. The results
may provide a way to rationally identify subtypes of cancers that
are driven by distinct risk loci. If this is the case, then genome wide
association studies for cancer risk may benefit from typing
matched tumor DNA samples, in addition to germline DNA,
and performing an integrative analysis. Alleles that do not affect
risk predisposition may still yield important clues with respect to
acquired tumor traits, such as angiogenesis, tissue invasiveness,
evasion of apoptosis, etc. Functional studies, such as allele specific
RNA interference for protein coding regions or somatic cell knock-
in of alleles, may shed light on the mechanistic consequences of the
alleles.
In summary, we demonstrate that integrating information from
germline and tumor genomes can reveal aspects of tumor biology
that are not readily identified by studying each genome in
isolation.
Materials and Methods
Data sets
We obtained glioblastoma array data (GBM Publication Data
Freeze) from the ftp site of TCGA. We utilized three different data
types – germline genotypes, amplification status, and allelic
imbalance – from various hybridization-based platforms, down-
loaded from the TCGA ftp site. First, germline SNP genotypes
(Illumina platform) for all normal samples were obtained. Second,
we accessed copy number segmentation data (from Affymetrix
SNP array 6.0, Illumina HumanHap550, and Agilent CGH array
244A) for tumor samples, providing genomic regions for each
individual that are inferred to have constant copy number along
with the estimated ‘‘raw’’ (non-integer) copy number of that
segment. Third, we obtained the raw allelic A and B signals for all
samples (Illumina BAF measure), tumor and normal. This
provides a raw measure of allelic imbalance, commonly termed
Figure 4. Selective allelic amplification and expression of SNPs in DOCK4 and EGFR. The SNP rs6959338 in DOCK4 shows preferential
amplification of the T allele (upper left), as well as higher expression levels in samples amplifying T instead of C (upper right). Similarly, rs13222385
shows preferential allelic amplification (lower left) and expression (lower right).
doi:10.1371/journal.pgen.1001086.g004
Integrating Germline and Tumor Genomic Data
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BAF~ Bsignal ðÞ = sumofAandBsignals ðÞ :
We also obtained Supplementary Table 7 from the Wrensch et al
GWAS [15], which lists 406 SNPs with p,0.001 for association
with high grade glioma comparing cases from San Francisco
Bay Area Adult Glioma Study, 1997–2006 (AGS) and the
Cancer Genome Atlas (TCGA) to AGS and Illumina controls
(iControls).
Calling amplification
For each of the three platforms (Affymetrix, Agilent, and
Illumina), we first inferred amplification at all 1.3 million
autosomal SNPs represented by the Affymetrix and Illumina
arrays combined, as follows. First, for each sample, all SNPs
harbored in each genomic segment from the sample’s copy
number segmentation file (see above) are assigned that segment’s
raw copy number. A SNP is called amplified by the platform in a
tumor sample if its raw copy number in that sample exceeds its
raw copy number in all normal samples. This conservative
amplification calling procedure accounts for local probe intensity
effects, and avoids miscalling germline copy number variants as
somatic amplifications. Note that this procedure, while conserva-
tive, is designed to include single-copy gains as well as high-level
amplification events. Finally, for all downstream analyses, a sample
is considered to harbor an amplification at a SNP if it is called
amplified by at least two of the three platforms.
Calling the amplified allele
For each SNP, we restrict the remainder of our analysis to
individuals that are both heterozygous in the germline and
amplified in the tumor at the SNP site. For each of these samples,
we aim to determine which of the two alleles is amplified. Towards
this end, we exploit the BAF measure described above. Since each
sample is heterozygous in the germline, we expect the SNP’s BAF
measure to be near 0.5 in the germline. A tumor BAF larger than
0.5 is indicative of B allele amplification, and a BAF smaller than
0.5 is indicative of A allele amplification. However, bias in A and B
intensity measures can result in deviations from these expectations.
We therefore rely on the deltaBAF measure, defined as
deltaBAF~BAFtumor-BAFmatchednormal:
The expectation here is that A (respectively, B) allele amplification
will result in a negative (respectively, positive) deltaBAF value. To
avoid erroneous deltaBAF calls due to noisy probe intensities, we
only have confidence in allele calls where |deltaBAF| .0.05.
That is, for heterozygous (in the germline) samples that are
amplified (in the tumor), we call A allele amplification if deltaBAF
,20.05 and B allele amplification if deltaBAF .0.05.
ADT P-values
The procedure described above yields sample counts for A
amplification and B amplification at each SNP. Let nA and nB,
respectively, denote these counts. Under the null hypothesis of
random allelic amplification, nA follows a Binomial(nA + nB, 0.5)
distribution. In other words, if there is no causal allele or site
within an amplified region, the distortion signature of each SNP
within the amplified region should conform to the null signature
on the binomial distribution. Therefore, a (two-sided) P-value
testing preferential allelic amplification may be performed by
comparing nA with this distribution in the obvious manner. The
chance of a non-causal/non-associated allele within an amplified
region being randomly selected enough times to result in a
distortion (i.e. false positive) is a, where a represents a chosen level
of significance as described in the following section.
Permutation analysis and quantile-quantile (qq-)plot
Although not a genome-wide association scan, our approaches
comprise many tests whose correlations are manifold and
complicated. Furthermore, some regions harbor more amplifica-
tions than others and therefore have a higher a priori likelihood of
displaying allelic distortion even under the null hypothesis.
Therefore, analytically determining genome-wide significance
from the test statistics is not straightforward. To address this, we
developed a permutation procedure that assesses the significance
of our results. For each run of the procedure, we first randomly
determined – at each sample chromosome pair – whether to swap
amplification status from the amplified allele to the non-amplified
allele at all amplified (in the tumor) SNPs on the chromosome.
This preserves haplotype and amplicon structure while destroying
correlation between the two. We then recomputed the test
statistics across the genome. In this manner, the amplification
status of the samples is preserved, and we are randomly sampling
from the null situation of non-preferential (random) amplification.
For the ADT test, these simulations produced an average of 114
SNPs (95% confidence interval 98–132) surpassing the 0.005
threshold. For the qq-plot, the qth null P-value quantile was
estimated by averaging the qth quantiles of P-values from 1000
permutations. Finally, the significance of the overlap between the
ADT SNPs and the Wrensch et al GWAS SNPs was assessed by
permuting, 1000 times, and retaining the 139 most significant
SNPs for each permutation (since our actual data generated 139
top SNPs). These number of SNPs in each permutation that
intersected with the Wrensch list was tallied for each permutation,
which yielded the expected distribution expected by chance.
GO analysis
For our GO analyses, we compared the gene list with a ‘‘gene
universe’’ comprised of all genes that had any a priori chance of
demonstrating preferential allelic amplification, at the P,0.005
nominal level, in our data. For a given gene, this depends upon
many factors, including amplification frequency and allele
frequencies of nearby array SNPs. We restricted the gene universe
to genes that were within 100 kb of a HumanHap550 array SNP
that is heterozygous and amplified in at least nine of our samples.
This is reasonable, as these are the only genes (by definition) that
have an a priori chance of having an associated SNP with ADT P-
value below 0.005. This left 2696 genes as a reference set. Using
the Ontologizer [37] software, we assessed our gene lists for
enrichment in GO terms, as compared with this reference gene
universe, using the Term-For-Term method and Benjamini-
Hochberg correction.
Gene co-amplification analysis
For each pair of genes, we constructed a 262 table of counts for
number of samples in each category of amplification/non-
amplification status for each gene. Using this table, we computed
the odds ratio estimate for correlation between amplification of the
genes, and assessed its significance using Fisher’s exact test. For
genes X and Y, this corresponds to the ratio of the odds of gene X
being amplified in a sample with gene Y amplified to the odds of
gene X being amplified in a sample without gene Y amplified.
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Expression levels from the Affymetrix 133A array were
downloaded from the TCGA website. For each gene/SNP
combination, expression differences between samples expressing
each of the two alleles were computed using the non-parametric
Wilcoxon rank sum test. The test was one-sided, since there was an
a priori hypothesis that the preferentially amplified allele would
result in a higher expression level.
Supporting Information
Figure S1 Proportion of individuals (out of 178) amplified in the
tumor, at each Illumina HumanHap550 SNP.
Found at: doi:10.1371/journal.pgen.1001086.s001 (1.01 MB TIF)
Figure S2 The number of individuals (out of 178) heterozygous
in the germline and amplified in the tumor, at each Illumina
HumanHap550 SNP.
Found at: doi:10.1371/journal.pgen.1001086.s002 (1.13 MB TIF)
Figure S3 (A) Chromosome 7: Condensed Haploview r2 LD
Plot for the three ADT hits (rs10255873, rs10267828, rs1557841)
in NXPH1. This condensed plot does not display SNPs in the
region that are not ADT hits. The plot indicates that the SNPs are
in LD in HapMap CEU data. (B) Chromosome 7: Condensed
Haploview r2 LD Plot for the five ADT hits (rs6963353, rs40,
rs2107479, rs1467344, rs10950366) in THSD7A. This condensed
plot does not display SNPs in the region that are not ADT hits.
The plot indicates that the latter two SNPs are in LD in HapMap
CEU data. (C) Chromosome 7: Condensed Haploview r2 LD Plot
for the seven ADT (rs2530552, rs425990, rs2530571, rs324389,
rs10267134, rs10278663, rs17199888) in NPSR1. This condensed
plot does not display SNPs in the region that are not ADT hits.
The plot indicates that the first three SNPs are in reasonable LD in
HapMap CEU data, and the same holds for the latter three SNPs.
Any blank red blocks indicate r2 =1.0 (100). (D) Chromosome 7:
Condensed Haploview r2 LD Plot for the three ADT hits
(rs6965611, rs2464946, rs11238181) in a region with no known
gene. This condensed plot does not display SNPs in the region that
are not ADT hits. The plot indicates that the first two SNPs
exhibit some LD in the HapMap CEU data.
Found at: doi:10.1371/journal.pgen.1001086.s003 (1.09 MB TIF)
Figure S4 (A) Chromosome 7: Condensed Haploview r2 LD Plot
for the three ADT hits (rs1963647, rs262375, rs264375) in RELN.
Thiscondensed plot doesnotdisplaySNPs intheregionthat arenot
ADT hits. The plot indicates that the SNPs display somelevel of LD
in HapMap CEU data. (B) Chromosome 7: Condensed Haploview
r2 LD Plot for the four ADT hits (rs10273020, rs4730037,
rs4367471, rs4132013) in LHFPL3. This condensed plot does not
display SNPs in the region that are not ADT hits. The plot reveals
that the first two SNPs are in strong LD in HapMap CEU data, as
blank red blocks indicate r2 =1.0 (100). The latter two SNPs also
show LD in HapMap CEU data. (C) Chromosome 7: Condensed
Haploview r2 LD Plot for the three ADT hits (rs9641684,
rs2189601, rs9969220) in CADPS2. This condensed plot does not
display SNPs in the region that are not ADT hits. The plot reveals
that the first two SNPs are in LD in HapMap CEU data, but they
are not in LD with the third SNP.
Found at: doi:10.1371/journal.pgen.1001086.s004 (0.64 MB TIF)
Figure S5 (A) Chromosome 20: Condensed Haploview r2 LD
Plot for the six ADT hits (rs1923342, rs6131447, rs6109753,
rs6105047, rs13433297, rs6074591) proximal to ISM1. This
condensed plot does not display SNPs in the region that are not
ADT hits. Furthermore, the latter two SNPs (rs13433297,
rs6074591) could not be plotted with the former four due to
Haploview constraints. In any case, r2 values between the former
four and latter two SNPs were negligible in HapMap CEU data.
(B) Chromosome 20: Haploview r2 LD Plot for the four ADT hits
(rs8120608, rs367114, rs453573, rs6043472) within MACROD2.
The SNPs (rs8120608, rs6043472) could not be plotted with the
other two due to Haploview constraints. In any case, r2 values
between these two SNPs and the two plotted SNPs were negligible.
The plot indicates that the two plotted SNPs are in LD in
HapMap CEU data, as highlighted by the yellow circle. (C)
Chromosome 20: Condensed Haploview r2 LD Plot for the three
ADT hits (rs6044739, rs6075193, rs6080665) within PCSK2. This
condensed plot does not display SNPs in the region that are not
ADT hits. The plot clearly indicates that the first two SNPs are in
LD in HapMap CEU data, as any blank red blocks indicate
r2 =1.0 (100). The first two are in very weak LD with the third.
(D) Chromosome 20: Condensed Haploview r2 LD Plot for the
three ADT hits (rs4812744, rs6124601, rs6130470) proximal to
TOX2. This condensed plot does not display SNPs in the region
that are not ADT hits. The SNP rs4812744 could not be plotted
with the other two due to Haploview constraints. The plot clearly
indicates that the two plotted SNPs are in LD in HapMap CEU
data.
Found at: doi:10.1371/journal.pgen.1001086.s005 (0.67 MB TIF)
Figure S6 Gene Ontology acyclic directed graph showing the
most enriched terms and their ancestor terms. The significant
terms are colored in green, with darker shading indicating greater
statistical significance. The arrow colors indicate type of
relationship between the GO categories, with black signifying ‘‘is
a’’ and green signifying ‘‘regulates.’’
Found at: doi:10.1371/journal.pgen.1001086.s006 (1.16 MB TIF)
Table S1 Top-scoring SNPs using ADT analysis (p#0.005) from
178 TCGA samples.
Found at: doi:10.1371/journal.pgen.1001086.s007 (0.07 MB
XLS)
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